Eli Lilly and Company (NYSE:LLY) Shares Bought by Hazlett Burt & Watson Inc.

Hazlett Burt & Watson Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 2.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,498 shares of the company’s stock after purchasing an additional 40 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Eli Lilly and Company were worth $1,158,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of LLY. Wellington Management Group LLP raised its position in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock valued at $9,747,214,000 after acquiring an additional 2,012,129 shares in the last quarter. Saratoga Research & Investment Management acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $24,169,000. Prevail Innovative Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $3,628,000. Physician Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 23.2% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,406 shares of the company’s stock worth $1,085,000 after buying an additional 265 shares during the last quarter. Finally, Martin Currie Ltd. boosted its holdings in shares of Eli Lilly and Company by 137.9% in the 4th quarter. Martin Currie Ltd. now owns 37,422 shares of the company’s stock valued at $28,890,000 after buying an additional 21,689 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent research reports. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a report on Thursday, March 6th. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Finally, Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Stock Performance

LLY opened at $820.30 on Monday. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a market capitalization of $777.78 billion, a price-to-earnings ratio of 70.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The business has a 50 day moving average price of $844.31 and a two-hundred day moving average price of $835.77. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has initiated a stock buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.